Denali Therapeutics

Denali Therapeutics

CA - South SF
Biotechnology3 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Neurodegenerative therapies, BBB-crossing antibody

Denali Therapeutics is a life sciences company focused on Neurodegenerative therapies, BBB-crossing antibody.

Neurology
Employees
5000+
Open Jobs
0

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT05523206A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)
N/A
N/A
Clinical Trials (1)
NCT04007536A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
N/A
Phase 1
Phase 1
Clinical Trials (1)
NCT03757325Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
Phase 1
Phase 1
Clinical Trials (1)
NCT04557800A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT03710707Study to Evaluate DNL201 in Subjects With Parkinson's Disease
Phase 1
[14C]-DNL343
Healthy Volunteers
Phase 1
Clinical Trials (1)
NCT06281158A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT04551534A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT04581772A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT05006352A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
Phase 1
[14C] BIIB122
Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT04268784A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT07354724A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT07328451A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
Phase 1
tividenofusp alfa
Mucopolysaccharidosis II
Phase 1/2
Clinical Trials (1)
NCT04251026A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
Phase 1/2
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT06181136Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
Phase 1/2
Phase 2
BIIB122 225 mg
Parkinson Disease
Phase 2
Phase 2/3
Clinical Trials (1)
NCT05842941HEALEY ALS Platform Trial - Regimen G DNL343
Phase 2/3
tividenofusp alfa
Mucopolysaccharidosis II
Phase 2/3
Clinical Trials (1)
NCT05371613A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
Phase 2/3
tividenofusp alfa
Mucopolysaccharidosis II
Phase 2/3
Clinical Trials (1)
NCT06075537An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
Phase 2/3
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 17 clinical trials
H-1B (2023): 3 approvals

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
3
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub